[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364306-105":59,"doc-detail-364306-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","organoid-development-and-applications-in-gynecological-cancers-the-new-stage-of-tumor-treatment","Organoid development and applications in gynecological cancers: the new stage of tumor treatment","","Gynecologic cancers (GCs) including cervical, ovarian, endometrial, vulvar, and vaginal cancers impose major and rising health burdens on women worldwide. Standard modalities such as surgery, radiotherapy, and chemotherapy are limited by drug resistance, recurrence, and high mortality. Organoid technology enables in vitro models that preserve tumor histology and molecular heterogeneity, supporting studies of tumor biology, pathways, and immune microenvironments. Organoids also advance biomarker discovery, drug screening, and personalized therapy by better reflecting primary tumor genetics and expression than conventional cell lines and PDX models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/organoid-development-and-applications-in-gynecological-cancers-the-new-stage-of-tumor-treatment/364306/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/organoid-development-and-applications-in-gynecological-cancers-the-new-stage-of-tumor-treatment/364306.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are conventional treatments for gynecologic cancers often insufficient?","Question",{"text":112,"@type":113},"Surgery, radiotherapy, and chemotherapy can be hindered by drug resistance and recurrence. These limitations contribute to persistent disease burden and high mortality.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What advantages do tumor-derived organoids offer for cancer research?",{"text":117,"@type":113},"Organoid models replicate the tumor’s architecture and molecular heterogeneity, preserving key histological and genetic features. They help investigate tumor biology, molecular pathways, and the tumor immune microenvironment.",{"name":119,"@type":110,"acceptedAnswer":120},"How do gynecologic cancer organoids support precision medicine?",{"text":121,"@type":113},"Organoids enable biomarker discovery and drug screening while maintaining patient-tumor characteristics. This supports development of personalized therapeutic strategies based on primary tumor responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364306,1790195354,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Li etal. Journal of Nanobiotechnology (2025) 23:20  \n[https://doi.org/10.1186/s12951-024-03086-z](https://doi.org/10.1186/s12951-024-03086-z)  \nJournal of Nanobiotechnology  \n REVIEW Open Access  \nOrganoid development and applications in gynecological cancers: the new stage of tumor treatment  \nYang Li1†, Meiying Qin1†, Ning Liu1* and Chunmei Zhang1*  \nAbstract  \nGynecologic cancers (GCs), including cervical cancer (CC), ovarian cancer (OC), endometrial cancer (EC), as well as vulvar and vaginal cancers, represent major health threats to women, with increasing incidence rates observed globally. Conventional treatments, such as surgery, radiation therapy, and chemotherapy, are often hindered by challenges such as drug resistance and recurrence, contributing to high mortality rates. Organoid technology has emerged as a transformative tool in cancer research, offering in vitro models that closely replicate the tumor cell architecture and heterogeneity of primary cancers. Tumor-derived organoids preserve the histological and molecular characteristics ofthe original tumors, making them invaluable for studying tumor biology, molecular pathways, and the tumor immune microenvironment. Furthermore, organoids play a crucial role in biomarker discovery, drug screening, and the development of personalized therapeutic strategies. In contrast to traditional cell lines and patient-derived xenograft (PDX) models, gynecologic cancer organoids accurately mirror the genetic mutations and specific gene expression profiles of primary tumors. This review provides an overview of recent advancements in the development of gynecologic cancer organoid models, highlighting their contributions to understanding disease mechanisms, facilitating drug discovery, and advancing precision medicine. It also addresses the potential and challenges of organoid technology, with a focus on its role in advancing personalized treatment approaches for GCs.  \nKeywords Organoids, Tissues, Gynecologic cancers (GCs), Precision medicine, Drug screening  \nIntroduction  \nGynecological cancers (GCs) include ovarian cancer (OC), cervical cancer (CC), endometrial cancer (EC), vulvar and vaginal cancers, and fallopian tube cancer [1] . Among these, OC, CC, and EC are the most common malignancies of the female reproductive system,  \n†Yang Li and Meiying Qin contribute equally to the article.  \n*Correspondence:  \nNing Liu [ningliu@cmu.edu.cn](ningliu@cmu.edu.cn)[ ](ningliu@cmu.edu.cn)Chunmei Zhang [zhangchm@sj-hospital.org](zhangchm@sj-hospital.org)  \n1 Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning, China  \nposing significant threats to women’s lives and health and representing a global public health concern [2–4] . Particularly, OC is difficult to diagnose early due to its hidden location, with over half of patients presenting with distant metastasis at diagnosis [5–8] . While early detection techniques have improved cure rates for EC and CC, treatment options remain limited for cases of recurrence and metastasis [9–11] . Currently, the treatment of GCs primarily involves a comprehensive approach, including surgery, radiotherapy, chemotherapy, and targeted therapy [12, 13] . However, due to the unique anatomical relationships of GCs, complete surgical resection is challenging, leading to high recurrence rates and often impacting patients’quality of life post-surgery. Radiotherapy mainly utilizes intracavitary  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this li","cbCaijVRp51RgXmi","https://ap.wps.com/l/cbCaijVRp51RgXmi","pdf",7049578,29,"English","# Introduction\n## Gynecological cancers and current treatment challenges\n## Rationale for organoid models\n# Organoid development and applications","[{\"question\":\"Why are conventional treatments for gynecologic cancers often insufficient?\",\"answer\":\"Surgery, radiotherapy, and chemotherapy can be hindered by drug resistance and recurrence. These limitations contribute to persistent disease burden and high mortality.\"},{\"question\":\"What advantages do tumor-derived organoids offer for cancer research?\",\"answer\":\"Organoid models replicate the tumor’s architecture and molecular heterogeneity, preserving key histological and genetic features. They help investigate tumor biology, molecular pathways, and the tumor immune microenvironment.\"},{\"question\":\"How do gynecologic cancer organoids support precision medicine?\",\"answer\":\"Organoids enable biomarker discovery and drug screening while maintaining patient-tumor characteristics. This supports development of personalized therapeutic strategies based on primary tumor responses.\"}]","Organoid development and applications in gynecological cancers: the new stage of tumor treatment | PDF",1790156854,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23d47dacd32e40ad479007bd247a8ff5.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53054dc63e9ee77cbbbc8dd9fa38ea3c.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48699313c7dd3cdf6d83ed0a5015be8b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6c2b9908c8336899a18eadd44b9bc1d.webp",980,1301]